Efficacy and Safety Study of Moxidectin in Adults With Scabies
NCT05875441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2025-05-04
Summary
Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.
Conditions
- Scabies
Interventions
- DRUG
-
Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
- DRUG
-
Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
- DRUG
-
Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
- DRUG
-
16 placebo capsules will be administered as a single dose.
Sponsors & Collaborators
-
Medicines Development for Global Health
lead OTHER
Principal Investigators
-
Richard L Fernandez, MD · Advance Care and Clinical Trials
-
Jorge Lopez, MD · Hospital y Clinica Bendana
-
Daisy Blanco, MD · Instituto Dermatologico Dominicano y Cirugia de Pie
-
Jorge Castillo Molina, MD · Affinity Clinical Research Services
-
Patricia A Zuniga Munoz, MD · Derclinic
-
Laura B Vargas Rivas, MD · Vargas Clinic
-
Gilberto Perez, MD · Evolution Clinical Trials
-
Armando Pineda-Velez, MD · Medical Research of Westchester, Inc
-
Bruce Torkan, MD · LA Universal Research Center, Inc
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-23
- Primary Completion
- 2024-11-27
- Completion
- 2025-02-11
- FDA Drug
- Yes
Countries
- United States
- Dominican Republic
- El Salvador
- Honduras
Study Locations
More Related Trials
-
Ivermectin Safety in Small Children
NCT04332068 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT00790998 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT06800248 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
NCT00340691 ·Status: COMPLETED ·Phase: PHASE2
-
Emodepside Phase II Trial for Treatment of Onchocerciasis
NCT05180461 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
NCT03084952 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Ivermectin Metabolites on Mosquito Survival
NCT03690453 ·Status: COMPLETED ·Phase: PHASE4
-
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
NCT00628719 ·Status: COMPLETED ·Phase: PHASE3
-
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
NCT00233545 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults
NCT02337855 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
NCT01380314 ·Status: COMPLETED ·Phase: PHASE2
-
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
NCT05957978 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
NCT06000514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
NCT05679479 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
NCT00111514 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome
NCT00128180 ·Status: COMPLETED ·Phase: PHASE2
-
Miltefosine for Mucosal Leishmaniasis
NCT00373776 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
NCT00317629 ·Status: TERMINATED ·Phase: PHASE3
-
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
NCT03096457 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
NCT00255567 ·Status: COMPLETED ·Phase: PHASE3
-
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
NCT01032187 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
NCT03110757 ·Status: COMPLETED ·Phase: PHASE1
-
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
NCT00469495 ·Status: COMPLETED ·Phase: NA
-
Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP
NCT01142765 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Mucosal Bolivian Leishmaniasis
NCT04799236 ·Status: RECRUITING ·Phase: PHASE3